Clustering of metastable states using the first 50 ns of post-translational folding trajectories of CAT-III with ligand bound. by Yang Jiang (46459)

Flow chart of the study procedures. by Kazuhiko Ikeuchi (9234268)

“…In the multivariable analysis, higher age (predicted monthly RPR relative change on the log2 scale 0.23/10 years [95% confidence interval [CI], 0.090–0.37]), history of syphilis (0.36 [95% CI, 0.07–0.65]), and a lower ratio of RPR at treatment initiation/diagnosis (−0.52/every 10-fold increase [95% CI, −0.81 to −0.22]) were associated with a slower RPR decrease after treatment.…”

Temporal changes in the RPR titer from before to after treatment. by Kazuhiko Ikeuchi (9234268)

Fold change with steady state myocardial mRNA levels for components of the inflammasome. by Stephanie L. Samani (17896610)

Subjects:

Performance of selected antimalarials against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

Primers used for analysis of four SNPs in one gene. by Winnie Okore (14139712)

Subjects:

Number of samples per site during the study period. by Winnie Okore (14139712)

Subjects:

Performance of selected drugs against field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> susceptibility responses of field isolates to antimalarials during the study period. by Winnie Okore (14139712)

Subjects:

<i>Pfmrp1</i> gene SNPs data during the study period. by Winnie Okore (14139712)

Subjects:

Frequency of SNPs in <i>Pfmrp1</i> gene in field isolates during the study period. by Winnie Okore (14139712)

Subjects:

<i>In vitro</i> 95% CI lower and upper mean susceptibility responses of field isolates to antimalarials. by Winnie Okore (14139712)

Subjects:

(a) Mycelial diameter (mm) determination on PDA plates, (b) Inhibition diameters, and (c) inhibition percentages of <i>Aspergillus flavus</i> treated with <i>U. epigea</i> extract... by Martha Cebile Jobe (21175426)

Nucleotide sequence alignment of aflatoxin genes <i>Nor, Omt</i>, <i>Ver</i> and <i>aflR</i> treated with <i>U. epigea</i> extract, Ag/ZnO (Biosynthesized and Conventional) nanopar... by Martha Cebile Jobe (21175426)

Comparison of the performance of the 10 CV (10 fold cross validation) model and the permutated model. by Sakuni Rankothgedera (11457923)

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

TPM values of the 48 nuclear receptors at 2, 4, 6, and 8 weeks and TPM values of PCR-tagged gene insertion at 10 days. by Yoshinori Hasegawa (308240)

Size distributions of ucfDNA molecules. by Meihui Chen (1670020)

Analysis of ucfDNA in DHSs between control and age-comparable bladder cancer groups. by Meihui Chen (1670020)

TUDCA decreases ER stress in HOX neonatal rat lungs. by Kirkwood A. Pritchard Jr. (13449794)

“…<p>(<b>A</b>) The expression levels of ER stress markers (P-PERK 0.6±0.1-fold, p<0.001, n = 5; PERK 0.7±0.1-fold, p = 0.00364, n = 5; P-IRE1α 0.6±0.0-fold, p<0.001, n = 5; IRE1α 0.6±0.1-fold, p<0.001, n = 5; GRP78 0.8±0.1-fold, p<0.001, n = 5; cleaved ATF6 0.1±0.0-fold, p<0.001, n = 5; spliced XBP1 0.3±0.0-fold, p<0.001, n = 5; 2 males and 3 females) are all decreased while the N-glycosylated VEGFR2 is increased (3.5±0.2-fold, p<0.001, n = 5) in HOX neonatal lungs at P10 indicating TUDCA can attenuate hyperoxia-induced ER stress. …”